Panacea Biotec shares rally 5% as co gets UNICEF supply order worth Rs 127 crore

Shares of Panacea Biotec rose 4.99% on Thursday to the day's high of Rs 456 after the company received a Letter of Award from UNICEF for the supply of a polio vaccine worth approximately US$ 14.95 million (Rs 127 crore) in CY2025.

“We are delighted to inform you that Panacea Biotec Limited (“the Company”) has received a Letter of Award from UNICEF for the supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth approximately US$ 14.95 million (Rs 127 crore),” the company said in its press release on Tuesday.

UNICEF will require bOPV supplies for the Africa/Asia region as per the orders.


The company posted a profit of Rs 4.8 crore in the quarter ending September 30, 2024, after three consecutive quarters of losses.

Meanwhile, the company witnessed QoQ revenue growth of 27.18%, the highest in the last three years.

The stock has delivered a 3-year return of 126.6%, compared to the Nifty Smallcap 100’s return of 72.66%.

Panacea Biotec Ltd., incorporated in 1984, is a small-cap company with a market capitalization of Rs 2,653.69 crore, operating in the pharmaceuticals sector.